290 related articles for article (PubMed ID: 11795600)
1. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
2. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
3. Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol.
Silvestrini A; Meucci E; Vitali A; Giardina B; Mordente A
Chem Res Toxicol; 2006 Nov; 19(11):1518-24. PubMed ID: 17112240
[TBL] [Abstract][Full Text] [Related]
4. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
7. Molecular pharmacology of the interaction of anthracyclines with iron.
Xu X; Persson HL; Richardson DR
Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.
Olson RD; Mushlin PS
FASEB J; 1990 Oct; 4(13):3076-86. PubMed ID: 2210154
[TBL] [Abstract][Full Text] [Related]
9. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs.
Mordente A; Silvestrini A; Martorana GE; Tavian D; Meucci E
Drug Metab Dispos; 2015 Nov; 43(11):1691-701. PubMed ID: 26265744
[TBL] [Abstract][Full Text] [Related]
11. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
12. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Menna P; Minotti G; Salvatorelli E
Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
[TBL] [Abstract][Full Text] [Related]
13. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
14. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
Minotti G; Cairo G; Monti E
FASEB J; 1999 Feb; 13(2):199-212. PubMed ID: 9973309
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
16. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
17. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
18. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage.
Fogli S; Nieri P; Breschi MC
FASEB J; 2004 Apr; 18(6):664-75. PubMed ID: 15054088
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of anthracycline-induced cardiotoxicity and its prevention.
Horenstein MS; Vander Heide RS; L'Ecuyer TJ
Mol Genet Metab; 2000; 71(1-2):436-44. PubMed ID: 11001837
[TBL] [Abstract][Full Text] [Related]
20. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
